Quantcast

Latest Immunosuppressive drug Stories

2009-08-12 18:35:00

DEERFIELD, Ill., Aug. 12 /PRNewswire/ -- Astellas Pharma US, Inc. ("Astellas") announced today an update regarding the status of the request for emergency relief and preliminary injunction from the U.S. Food and Drug Administration's (FDA) decision regarding its Citizen Petition. The company's requests have been denied by the U.S. District Court in Washington, D.C. The company is disappointed in the court's decision and is currently evaluating its next course of action. The Citizen...

2009-08-10 22:52:00

DEERFIELD, Ill., Aug. 10 /PRNewswire/ -- Astellas Pharma US, Inc. ("Astellas") announced today that the U.S. Food and Drug Administration (FDA) has substantially denied the company's Citizen Petition to ensure the safe and effective use of immunosuppressants (also called anti-rejection medications) used to prevent rejection in organ transplant patients. In their petition, Astellas requested that the FDA take additional measures to protect transplant recipients, a unique and vulnerable...

2009-07-20 10:10:00

CHICAGO, July 20 /PRNewswire-FirstCall/ -- At this year's American Association for Clinical Chemistry (AACC) meeting, Waters Corporation (NYSE: WAT) is introducing clinical scientists to its expanded portfolio of new products for clinical and research laboratories including a new research use only (RUO) kit for quantitative measurement of Tacrolimus, Sirolimus, Everolimus, and Cyclosporin A. A highlight of the AACC meeting, the Waters(R) MassTrak(TM) Immunosuppressants XE RUO Kit provides...

2009-07-14 12:00:57

The U.S. Food and Drug Administration is ordering manufacturers of some immunosuppressant drugs used in kidney transplants to change their labeling. The FDA said the updated labels must reflect an increased risk of infections. The required label changes affect drugs used to help prevent rejection of transplanted organs. The drugs are Rapamune (sirolimus), Sandimmune (cyclosporine), and three generic drugs, Neoral (cyclosporine modified), Cellcept (mycophenolate mofetil) and Myfortic...

2009-07-08 14:00:25

Transplant patients rely on drugs to prevent graft rejection, but at the cost of serious side effects. The class of immunosuppressive drugs known as calcineurin inhibitors (examples are cyclosporine and tacrolimus) can damage patients' kidneys and lead to high blood pressure, among other problems.A combination of treatments can effectively replace calcineurin inhibitors in preventing graft rejection when kidney transplants are performed on monkeys, scientists at the Emory Transplant Center...

2009-06-04 14:11:02

A drug derived from the hydrangea root, used for centuries in traditional Chinese medicine, shows promise in treating autoimmune disorders, report researchers from the Program in Cellular and Molecular Medicine and the Immune Disease Institute at Children's Hospital Boston (PCMM/IDI), along with the Harvard School of Dental Medicine. In the June 5 edition of Science, they show that a small-molecule compound known as halofuginone inhibits the development of Th17 cells, immune cells recently...

2009-05-31 16:30:00

The results of these studies will be presented during the American Transplant Congress in Boston, MAMay 30 - June 3, 2009 COLUMBIA, Md., May 31 /PRNewswire/ -- A study conducted at Westchester Medical Center in Valhalla, NY examined liver transplant recipients to determine whether the use of the ImmuKnow assay to guide immunosuppression therapy would reduce drug toxicity and drug-related adverse events. (Logo: http://www.newscom.com/cgi-bin/prnh/20090424/NE99362LOGO ) According to Dr....

2009-05-28 08:00:00

DEERFIELD, Ill., May 28 /PRNewswire/ -- The Food and Drug Administration (FDA) has granted Astellas Pharma US, Inc. approval for the use of Prograf(R) (tacrolimus) in conjunction with mycophenolate mofetil (MMF) for the prevention of organ rejection in kidney transplant recipients. Prograf is a cornerstone therapy for preventing transplant rejection in liver, kidney and heart transplant recipients. The approval came on May 19, 2009 in response to a Supplemental New Drug Application (sNDA)...

2009-04-14 07:30:00

Trial to Evaluate Safety of CCL2-LPM for Inflammatory Kidney Disease SAN FRANCISCO, April 14 /PRNewswire/ -- Osprey Pharmaceuticals U.S.A., Inc. announced today that patient dosing has commenced in a Phase Ib clinical trial of the company's lead compound, CCL2-LPM, for the treatment of IgA nephropathy, an inflammatory kidney disease. Osprey Pharmaceuticals U.S.A. is developing novel chemokine-enzyme fusion protein therapeutics, known as Leukocyte Population Modulators (LPMs), for the...

2009-04-09 14:56:21

An Australian-led scientific team says it's developed a therapy that might eventually negate the need for immunosuppressive drugs after organ transplants. Professor Jonathan Sprent and Dr. Kylie Webster from Sydney's Garvan Institute of Medical Research, in collaboration with U.S. and Swiss colleagues, successfully tested a method in experimental mice of temporarily adjusting the immune system to allow the receipt of a tissue transplant and accept it as 'self'. They said at no stage, during...


Word of the Day
barratry
  • The offense of persistently instigating lawsuits, typically groundless ones.
  • An unlawful breach of duty on the part of a ship's master or crew resulting in injury to the ship's owner.
  • Sale or purchase of positions in church or state.
This word ultimately comes from the Old French word 'barater,' to cheat.
Related